Literature DB >> 9889959

Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice.

J A Louis1, F Conceiçao-Silva, H Himmelrich, F Tacchini-Cottier, P Launois.   

Abstract

Resistance and susceptibility to infection with the intracellular parasite, Leishmania major, are mediated by parasite-specific CD4+ Th1 and Th2 cells, respectively. It is well established that the protective effect of parasite-specific CD4+ Th1 cells is largely dependent upon the IFN-gamma produced. However, recent results indicate that the effect of Th1 cells on resolution of lesions induced by L. major in genetically resistant mice also requires a functional Fas-FasL pathway of cytotoxicity. In contrast to resistant mice, susceptible BALB/c mice develop aberrant Th2 responses following infection with L. major and consequently suffer progressive disease. These outcomes clearly depends upon the production of interleukin 4 (IL-4) early after infection. We have shown that a burst of IL-4 mRNA, peaking in draining lymph nodes of BALB/c mice 16 hrs after infection, occurs within CD4+ T cells that express V beta 4-V alpha 8 T cell receptors. In contrast to control and V beta 6-deficient mice, V beta 4-deficient BALB/c mice were resistant to infection, demonstrating the role of these cells in Th2 development. The early IL-4 response was absent in these mice, and Th1 responses occurred following infection. The LACK antigen of L. major induced comparable IL-4 production in V beta 4-V alpha 8 CD4+ T cells. Thus, the IL-4 required for Th2 development and susceptibility to L. major is produced by a restricted population of V beta 4-V alpha 8 CD4+ T cells after cognate interaction with a single antigen from this complex parasite. The IL-4 produced rapidly by these CD4+ T cells induces within 48 hours a state of unresponsiveness to IL-12 among parasite-specific CD4+ T cell precursors by downregulating the IL-12 receptor beta 2 chain expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9889959     DOI: 10.1007/978-1-4615-5355-7_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Protective immunity and vaccination against cutaneous leishmaniasis.

Authors:  Ifeoma Okwor; Zhirong Mou; Dong Liu; Jude Uzonna
Journal:  Front Immunol       Date:  2012-05-29       Impact factor: 7.561

2.  Unbalanced inflammatory reaction could increase tissue destruction and worsen skin infectious diseases - a comparative study of leishmaniasis and sporotrichosis.

Authors:  F N Morgado; L M V de Carvalho; J Leite-Silva; A J Seba; M I F Pimentel; A Fagundes; M F Madeira; M R Lyra; M M Oliveira; A O Schubach; F Conceição-Silva
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

Review 3.  Unraveling the Role of Immune Checkpoints in Leishmaniasis.

Authors:  Rafael de Freitas E Silva; Esther von Stebut
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

4.  Malaria-Cutaneous Leishmaniasis Co-infection: Influence on Disease Outcomes and Immune Response.

Authors:  Raquel A Pinna; Danielle Silva-Dos-Santos; Daiana S Perce-da-Silva; Joseli Oliveira-Ferreira; Dea M S Villa-Verde; Paula M De Luca; Dalma M Banic
Journal:  Front Microbiol       Date:  2016-06-27       Impact factor: 5.640

5.  Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A.

Authors:  Mary-Anne Hartley; Eliane Bourreau; Matteo Rossi; Patrik Castiglioni; Remzi Onur Eren; Florence Prevel; Pierre Couppié; Suzanne M Hickerson; Pascal Launois; Stephen M Beverley; Catherine Ronet; Nicolas Fasel
Journal:  PLoS Pathog       Date:  2016-09-22       Impact factor: 6.823

Review 6.  Apoptotic mimicry as a strategy for the establishment of parasitic infections: parasite- and host-derived phosphatidylserine as key molecule.

Authors:  João Luiz Mendes Wanderley; Renato Augusto DaMatta; Marcello André Barcinski
Journal:  Cell Commun Signal       Date:  2020-01-15       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.